Social Links

Follow on Facebook Follow on Twitter Follow on G+Follow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS Interactive DVD Series & Seminars

Autism: an emerging neuroimmune disorder in search of therapy

 

 

 

Expert Opin Pharmacother. 2009 Jul 29. [Epub ahead of print]

 

Autism: an emerging 'neuroimmune disorder' in search of therapy.

 

Theoharides TC, Kempuraj D, Redwood L. Director, Molecular Immunopharmacology and Drug Discovery Laboratory,Tufts University School of Medicine, Tufts Medical Center, Department of Pharmacology and Experimental Therapeutics, and Departments of Biochemistry, Internal Medicine, and Psychiatry, Molecular Immunopharmacology and Drug Discovery Laboratory, 136 Harrison Avenue, Boston, MA 02111, USA +1 617 636 6866 ; +1 617 636 2456 ; This email address is being protected from spambots. You need JavaScript enabled to view it. .

 

 

Background: Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by difficulties in communication and by repetitive and stereotypic behaviors, as well as by social impairment, attention, cognitive, and learning defects. ASDs present in early childhood and their prevalence has increased significantly to 1/150 children. Despite a number of theories, the actual reasons for this increase are still not clear. There is no reliable screening test, and no definite pathogenesis or curative therapy. Consequently, there is a major gap hampering development of effective treatments.

 

Objective: To review recent publications on ASDs pathogenesis and treatment with emphasis on neuroimmune processes and new therapeutic approaches.

 

Methods: Mostly original papers (450) on epidemiology, possible pathogenesis or treatment of ASDs in Medline from 1990 to May 2009 were reviewed. All authors contributed to this review.

 

Results/conclusion: Increased oxidative stress and immune dysregulation are present in ASDs. Mast-cell activation may contribute to gut-blood-brain barrier disruption and brain inflammation. No effective treatments have emerged. Well-designed clinical trials with nonpsychotropic drugs were few and ASD characteristics varied considerably, making conclusions difficult. Psychotropic drugs are often used for stereotypic and aggressive behaviors. Unique combinations with antioxidant and anti-inflammatory flavonoids hold promise. New potential translational research areas and possible treatments are suggested.

 

PMID: 19640207 [PubMed - as supplied by publisher]

 


 

 

Related Articles:

 

People in this conversation

  • It is fantastic to see a paper published in a mainstream medical journal that deals with the biomedical treatment opportunities in autism. While early intensive behavioural and cognitive interventions are efficacious in many cases, they do not result in a cure in most children. The pathophysiology of autism discussed in this article (i.e. oxidative stress, immune dysregulation, brain inflammation etc) and the novel nutritional treatments suggests offer another avenue of therapy with potentially long-lasting positive outcomes.

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner